In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Extra members will be enrolled with the discovered monotherapy dosign regimen. In Segment B, contributors will receive oral ruxolitinib and ABBV-744 is going to be specified as "include-on" therapy. In Section https://emilianobqdrf.blogmazing.com/31269745/abbv-744-cancer-treatment-clinical-trials-an-overview